Pharmafile Logo

UK Lifes Sciences

- PMLiVE

ICR researchers uncover new method for predicting bowel cancer risk in IBD patients

Approximately 500,000 people in the UK are affected by Crohn’s disease or ulcerative colitis

- PMLiVE

ICR researchers uncover genes responsible for tumour progression in prostate cancer

The findings could pave the way for new treatment approaches that improve patient outcomes

- PMLiVE

ICR study reveals how PARP inhibitor resistance develops in prostate cancer patients

The research could pave the way for the development of new drugs that prevent drug resistance

- PMLiVE

ICR researchers identify potential treatment approach for acute myeloid leukaemia

More than 3,100 people are diagnosed with the aggressive blood cancer in the UK every year

- PMLiVE

ICR researchers reveal benefits of personalised radiotherapy for bladder cancer patients

More than 130,000 patients are treated with radiotherapy on the NHS every year

- PMLiVE

ICR researchers identify new drug target for advanced prostate cancer patients

The team estimates that around 10% of patients have high levels of the BCL2 protein

- PMLiVE

ICR researchers identify new treatment pathway for rare set of childhood brain tumours

Gliomatosis cerebri is a highly aggressive glioma that affects 100 people in the US every year

- PMLiVE

Teva UK and Closed Loop Medicine partner to advance development of personalised medicines

The collaboration will utilise Closed Loop Medicine’s software as a medical device technology platform

- PMLiVE

6 trends shaping the future of personalized medicine

Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators.

Avalere Health

- PMLiVE

Personalised medicine: driving a need for greater diversity in clinical trials

Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today.

Innovative Trials

- PMLiVE

ICR appoints Kristian Helin as its new chief executive

Helin will join ICR in September from the Memorial Sloan Kettering Cancer Center in the US

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links